LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

Search

BioMarin Pharmaceutical Inc

Abrir

SetorSaúde

55.03 2.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

53.66

Máximo

55.03

Indicadores-chave

By Trading Economics

Rendimento

61M

186M

Vendas

-2.2M

745M

P/E

Médio do Setor

20.03

50.291

EPS

1.13

Margem de lucro

24.919

Funcionários

3,040

EBITDA

28M

224M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+75.93% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.9B

10B

Abertura anterior

52.67

Fecho anterior

55.03

Sentimento de Notícias

By Acuity

54%

46%

322 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de ago. de 2024, 11:30 UTC

Principais Notícias

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Comparação entre Pares

Variação de preço

BioMarin Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

75.93% parte superior

Previsão para 12 meses

Média 95.25 USD  75.93%

Máximo 120 USD

Mínimo 70 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para BioMarin Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

14

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

59.405 / 62.19Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

322 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.